Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000291) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
Macrocyclic peptide anti-CXCR4 CVX15
|
|||||
| Synonyms |
Macrocyclic peptide CVX15
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Highest Status | Research | |||||
| Sequence Length | 16 | |||||
| SBP Sequence |
>Macrocyclic peptide anti-CXCR4 CVX15
RR[Nal]CYQK[d-Pro]PYR[Cit]CRG[d-Pro] |
|||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS044 | [1] | ||||
| Scaffold Name | Macrocyclic peptide | |||||
| Scaffold Class | Non-Antibody | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| C-X-C chemokine receptor type 4 | Antagonist | Cancer metastasis [ICD-11: 2E2Z]; Human immunodeficiency virus type 1 infection [ICD-11: XN8LD] | N.A. | The Scripps Research Institute; Pfizer | [1] | |